Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by ...
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...
Kedrion announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its investigational treatment for Congenita...
Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to be...
The Muscular Dystrophy Association (MDA) called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, g...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...
SciSparc Ltd. announced that NeuroThera Labs Inc. , a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous sy...
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...
Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
Collaboration will investigate how continuous flow cellular engineering and donor-to-dose manufacturing expertise may advance scalable, non-viral process...
© 2025 Biopharma Boardroom. All Rights Reserved.
